A digital opinion leader (DOL) is a healthcare professional whose influence on how other clinicians, and often patients, think about a disease or treatment comes mainly from what they publish and discuss online. That can mean social platforms, podcasts, video, newsletters, or professional online communities. A DOL may hold no academic title and may never have led a trial, and still be the person many colleagues turn to when new data comes out. In medical affairs, the term is normally used for HCPs, although some marketers apply it to patient advocates and other online voices.
Quick answer: A DOL is an HCP who shapes clinical opinion through an online presence. A key opinion leader (KOL) earns influence through publications, trials, guideline work, and podium time. The two overlap, since many KOLs are now active online and some DOLs build their reputation online first. Medical affairs teams track them separately because digital reach and scientific standing do not always move together.
How a DOL differs from a KOL
A key opinion leader is recognized by peers through the traditional record: peer-reviewed papers, trial leadership, guideline committees, and invited talks. A 2025 study in the Journal of Medical Internet Research describes DOLs as usually qualified health care providers who shape opinion through online platforms. It notes that a growing number of traditional KOLs are becoming DOLs as their digital presence grows, while others, often early-career professionals, build their influence online rather than in academia. The same paper separates DOLs from social media influencers, who often have no formal medical training.
| Key opinion leader | Digital opinion leader | |
|---|---|---|
| Source of influence | Publications, trials, guidelines, podium | Online content and the audience it builds |
| Main audience | Specialists, guideline panels, academic peers | Practicing clinicians, trainees, sometimes patients |
| How influence is judged | Citations, trial roles, committee seats | Reach, who engages, accuracy and consistency of content |
| Speed | Months to years, through journals and meetings | Hours to days, often during a congress |
Why medical affairs pays attention to DOLs
Many clinicians now meet new data online, often before they read the paper. When a late-breaking abstract is presented, the first interpretation many physicians see is a thread or a short video from a colleague they follow. If that interpretation misses a limitation or overstates a subgroup, it spreads faster than any correction. Medical affairs does not control that conversation, but it should know who is shaping it and what they are saying.
DOLs also fill a gap in the expert map. A traditional KOL list built from publications and trial sites tends to miss community clinicians and younger specialists whose views carry weight with their peers. Some of those people are DOLs. Finding them early, especially before a launch, gives the field team a fuller picture of who influences practice in a therapeutic area.
How teams identify and assess DOLs
Follower count is a weak signal on its own. A clinician with a large consumer audience may have little influence on prescribers, while a specialist with a small following of peers may shape how a whole subspecialty reads a trial. Teams usually look at who engages with the content, whether the HCP posts regularly about the therapeutic area, how accurate and balanced the content is, and whether the person also holds a traditional role. The KOL tiering glossary notes that many teams now score digital reach as its own dimension, separate from scientific standing, so a DOL can be placed alongside KOLs without forcing one scale onto both.
The work starts with KOL identification. TikaMobile's KOL identification includes social media analysis that tracks an expert's online engagement, the topics and hashtags they post about, and the tone of what they say, next to their publications and trials.
Engaging DOLs within the rules
A DOL is an HCP first, so the usual rules apply. Medical affairs can hold scientific exchange with a DOL the same way it would with any expert. If the company pays a DOL for a service, the engagement needs a written contract, a documented need, and fair market value pay, and the payment is reportable like any other. Content a company pays for or shapes is generally treated as the company's own communication, so it goes through MLR review and the paid relationship has to be disclosed. A company cannot ask a DOL to say online what it could not say itself, including anything about unapproved uses.
Frequently asked questions
What does DOL mean in pharma?
DOL stands for digital opinion leader. It is a healthcare professional who shapes clinical opinion mainly through an online presence, such as social media, podcasts, video, or professional online communities.
Is a digital opinion leader the same as a key opinion leader?
No. A key opinion leader earns influence through publications, trials, guideline work, and speaking. A digital opinion leader earns it through online content and the audience that follows it. One person can be both, and many KOLs are now active online.
How do medical affairs teams find digital opinion leaders?
They look past follower counts to who engages with an HCP's content, how often the HCP posts about the therapeutic area, how accurate the content is, and whether the person also holds a traditional expert role. Many teams score digital reach as its own dimension within KOL tiering.
Can a pharma company pay a digital opinion leader?
Yes, for a bona fide service under a written contract at fair market value, with the payment reported like any other HCP payment. Content the company pays for or shapes goes through the company's review process, and the paid relationship must be disclosed.
If your team is building an expert map for a therapeutic area and wants to see online influence next to the traditional record, we can walk through it with experts from your own field.
Book a 20-minute walkthrough →
Sources
- Green A, Wu S, Di Pasquale A, Pang T. The Role of Digital Opinion Leaders in Dengue Prevention Through Health Promotion and Public Health Collaboration: Qualitative Semistructured Interview Study. Journal of Medical Internet Research. 2025;27:e70997. doi:10.2196/70997.
Glossary
November 1, 2026
